Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
CareDx (DE:1K9)
STUTTGART:1K9
CareDx (1K9) Stock Price & Analysis
0 Followers
1K9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.58 - €11.50
Previous Close€8.95
Volume0.00
Average Volume (3M)51.00
Market Cap
€491.78M
Enterprise Value€269.94M
Total Cash (Recent Filing)$268.18M
Total Debt (Recent Filing)$29.25M
Price to Earnings (P/E)N/A
Beta1.42
Next Earnings
May 09, 2024EPS Estimate
-€0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume51
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.91
Enterprise Value/Gross Profit1.29
Enterprise Value/Ebitda-3.51
Forecast
1Y Price Target
€13.93Price Target Upside55.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
CareDx News
PremiumCompany Announcements
CareDx Appoints John W. Hanna as New CEO and Board Member
PremiumCompany Announcements
CareDx Enhances Board with Financial Expert Riggsbee
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCareDx delivered a slight top-line revenue beat in Q4, with a revenue guide for the next year that surpasses average analyst expectations.
Operational EfficiencyCareDx demonstrated improved financial efficiency, reducing its cash burn significantly, and strategically repurchasing shares to create shareholder value.
Product DevelopmentCareDx is advancing additional data for HeartCare through its SHORE study, potentially expanding Medicare coverage for this innovative testing service.
Bears Say
Financial PerformanceNet loss significantly exceeded estimates, reflecting heightened financial stress.
Leadership UncertaintyThe ongoing search for a new CEO introduces uncertainty about the company's strategic direction.
Legal ChallengesRecent jury decision in patent infringement case implies potential financial burdens ahead.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
23.66% Other Institutional Investors
76.34% Public Companies and
Individual Investors
1K9 FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was €4.58 and its highest was €11.50 in the past 12 months.
What is CareDx’s market cap?
Currently, no data Available
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is May 09, 2024 which is in 2 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Feb 28, 2024. The company reported -€2.052 earnings per share for the quarter, missing the consensus estimate of -€0.415 by -€1.637.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is -€0.44.
How many shares outstanding does CareDx have?
Currently, no data Available
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of -€2.052 in its last earnings report, missing expectations of -€0.415. Following the earnings report the stock price went up 2.312%.
Which hedge fund is a major shareholder of CareDx?
Among the largest hedge funds holding CareDx’s share is ARK Investment Management LLC. It holds CareDx’s shares valued at 86M.
---
CareDx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.93 (55.75% Upside)
€13.93 (55.75% Upside)
Blogger Sentiment
Neutral
DE:1K9 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $70.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.33%
12-Months-Change
Fundamentals
Return on Equity
-54.98%
Trailing 12-Months
Asset Growth
-13.60%
Trailing 12-Months
Company Description
CareDx
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
---
1K9 Earnings Call
Q4 2024
0:00 / 0:00
---
1K9 Stock 12 Months Forecast
Average Price Target
€13.93
▲(55.75% Upside)
Technical Analysis
Best Analysts Covering 1K9
1 Year
1 Year Success Rate
4/18 ratings generated profit
1 Year Average Return
-20.24%
upgraded a buy rating 9 months ago
Copying Andrew Cooper's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -20.24% per trade.
---